Company Analysis
Sign in

Seres Therapeutics, Inc. (MCRB)

Nasdaq: MCRB · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2014
Full chart Alerts Compare
Grade4.6
◀ Past 3.2● Present 4.7▶ Future 5.3
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

30 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Seres Therapeutics, Inc.’s names, not what it holds today.

Patents granted
30
30 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 2 in 2024 and 3 in 2023
Applications published
54
5 of them in 2025
Names they are printed under
4
its own name, a former name
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals16
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Seres Therapeutics, Inc. its own name
US, as the owner printed on each patent. 4 more under the same name are not counted (printed in GB)
27 granted
28 published
Seres Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
20 published
Seres Health, Inc. a former name
US, as the owner printed on each patent
3 granted
3 published
Seres Health, Inc. a former name
named as the applicant on its applications, in US
0 granted
3 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 9, 202512,409,197Synergistic bacterial compositions and methods of production and use thereofPharmaceuticalsSeres Therapeutics, Inc.
Feb 4, 202512,214,002Compositions and methods for treating antibiotic resistancePharmaceuticalsSeres Therapeutics, Inc.
Sep 10, 202412,083,151Synergistic bacterial compositions and methods of production and use thereofPharmaceuticalsSeres Therapeutics, Inc.
Mar 5, 202411,918,612Synergistic bacterial compositions and methods of production and use thereofPharmaceuticalsSeres Therapeutics, Inc.
Aug 22, 202311,730,775Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereofPharmaceuticalsSeres Therapeutics, Inc.
Jul 18, 202311,701,394Compositions and methods for treating cholestatic diseasePharmaceuticalsSeres Therapeutics, Inc.
Jun 6, 202311,666,612Network-based microbial compositions and methodsPharmaceuticalsSeres Therapeutics, Inc.
Oct 11, 202211,464,812Synergistic bacterial compositions and methods of production and use thereofPharmaceuticalsSeres Therapeutics, Inc.
Oct 4, 202211,458,174Synergistic bacterial compositions and methods of production and use thereofPharmaceuticalsSeres Therapeutics, Inc.
Oct 4, 202211,458,173Synergistic bacterial compositions and methods of production and use thereofPharmaceuticalsSeres Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0367242DESIGNED BACTERIAL COMPOSITIONS AND USES THEREOFPharmaceuticalsSeres Therapeutics, Inc.
Sep 18, 20252025/0288625COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC RESISTANCEPharmaceuticalsSeres Therapeutics, Inc.
Feb 27, 20252025/0064869SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOFPharmaceuticalsSeres Therapeutics, Inc.
Jan 16, 20252025/0017984MANIPULATION OF TRYPTAMINE METABOLISMPharmaceuticalsSeres Therapeutics, Inc.
Jan 2, 20252025/0000915METHODS OF POPULATING A GASTROINTESTINAL TRACTPharmaceuticalsSeres Therapeutics, Inc.
Dec 12, 20242024/0408151COMPOSITIONS AND METHODSPharmaceuticalsSeres Therapeutics, Inc.
Oct 3, 20242024/0325464SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOFPharmaceuticalsSeres Therapeutics, Inc. · patent 12,409,197 granted from it
Jul 4, 20242024/0216444DESIGNED BACTERIAL COMPOSITIONSPharmaceuticalsSeres Therapeutics, Inc.
May 30, 20242024/0173367COMPOSITIONS AND METHODS FOR TREATING CHOLESTATIC DISEASEPharmaceuticalsSeres Therapeutics, Inc.
May 9, 20242024/0148803USE OF IMMUNOTHERAPY AND MICROBIOME MODULATION TO TREAT CANCERPharmaceuticalsSeres Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 12.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MCRB · research, not advice